{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:44:56Z","timestamp":1775594696850,"version":"3.50.1"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,10]]},"abstract":"ABSTRACT<\/jats:title>\n \n Wild-type penicillin-binding protein (PBP) 2b from penicillin-susceptible\n Streptococcus pneumoniae<\/jats:italic>\n had high affinity for ceftobiprole and penicillin (50% inhibitory concentrations [IC\n 50<\/jats:sub>\n s] of \u22640.15 \u03bcg\/ml) but not ceftriaxone (IC\n 50<\/jats:sub>\n of >8 \u03bcg\/ml). In clinical isolates, ceftobiprole and PBP 2b affinities were reduced 15- to 30-fold with a Thr-446-Ala substitution and further still with an additional Ala-619-Gly PBP 2b substitution. Ceftobiprole remained active (MICs of \u22641 \u03bcg\/ml) against all strains tested and behaved more like penicillin than ceftriaxone with respect to PBP 2b binding.\n <\/jats:p>","DOI":"10.1128\/aac.00590-10","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T03:06:43Z","timestamp":1281409603000},"page":"4510-4512","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Affinity of Ceftobiprole for Penicillin-Binding Protein 2b in\n Streptococcus pneumoniae<\/i>\n Strains with Various Susceptibilities to Penicillin"],"prefix":"10.1128","volume":"54","author":[{"given":"Todd A.","family":"Davies","sequence":"first","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenping","family":"He","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Bush","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2009"},{"key":"e_1_3_2_3_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 19th informational supplement. 2009"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.02.024"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00029-07"},{"key":"e_1_3_2_6_2","unstructured":"Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae (Spn) with varying penicillin susceptibilities 2008"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00238-06"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.829"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007170"},{"key":"e_1_3_2_10_2","first-page":"755","volume":"133","year":"1987","unstructured":"Hakenbeck, R., S. Tornette, and N. F. Adkinson. 1987. Interaction of non-lytic \u03b2-lactams with penicillin-binding proteins in Streptococcus pneumoniae. J. Gen. Microbiol.133:755-760.","journal-title":"J. Gen. Microbiol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.825-836.2001"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01082-07"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1273-1280.2002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3261-3264.2002"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1848-1855.2004"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00590-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00590-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:13:26Z","timestamp":1645474406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00590-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1128\/AAC.00590-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00590-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"2010-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}